Co-Authors
This is a "connection" page, showing publications co-authored by CHARLOTTE C SUN and LOIS M RAMONDETTA.
Connection Strength
2.912
-
Avoidable tragedies: Disparities in healthcare access among medically underserved women diagnosed with cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):500-5.
Score: 0.529
-
Work related stress among gynecologic oncologists. Gynecol Oncol. 2011 Nov; 123(2):365-9.
Score: 0.394
-
Religious and spiritual beliefs of gynecologic oncologists may influence medical decision making. Int J Gynecol Cancer. 2011 Apr; 21(3):573-81.
Score: 0.386
-
Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic. Gynecol Oncol. 2019 02; 152(2):328-333.
Score: 0.164
-
Nothing left to chance? The impact of locus of control on physical and mental quality of life in terminal cancer patients. Support Care Cancer. 2017 06; 25(6):1985-1991.
Score: 0.145
-
Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):553-8.
Score: 0.132
-
Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients. Gynecol Oncol. 2015 Aug; 138(2):388-93.
Score: 0.128
-
Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer. 2015 Jul; 23(7):2025-32.
Score: 0.125
-
Patient preferences for side effects associated with cervical cancer treatment. Int J Gynecol Cancer. 2014 Jul; 24(6):1077-84.
Score: 0.121
-
Surprising results regarding MASCC members' beliefs about spiritual care. Support Care Cancer. 2013 Nov; 21(11):2991-8.
Score: 0.113
-
A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011 Apr; 21(3):517-22.
Score: 0.097
-
Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer. 2009 May 01; 115(9):1867-74.
Score: 0.085
-
Social factors affecting treatment of cervical cancer: ethical issues and policy implications. Obstet Gynecol. 2008 Mar; 111(3):747-51.
Score: 0.078
-
Advanced cervical cancer treatment in Harris County: pilot evaluation of factors that prevent optimal therapy. Gynecol Oncol. 2006 Nov; 103(2):547-53.
Score: 0.069
-
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
Score: 0.046
-
Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018 06; 149(3):484-490.
Score: 0.039
-
Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
Score: 0.038
-
The Advance Care Planning Readiness Scale: Development and Validation of a Measure of Willingness to Discuss and Acceptance of End-of-Life Care in Gynecologic Cancer Patients. Int J Gynecol Cancer. 2017 05; 27(4):838-846.
Score: 0.037
-
Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients. Gynecol Oncol. 2016 09; 142(3):525-30.
Score: 0.035
-
Dying well: How equal is end of life care among gynecologic oncology patients? Gynecol Oncol. 2016 Feb; 140(2):295-300.
Score: 0.033
-
Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients. Gynecol Oncol. 2014 Nov; 135(2):244-8.
Score: 0.031
-
Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):323-8.
Score: 0.028
-
Ethics consultation on a gynecologic oncology service: an opportunity for physician education. J Cancer Educ. 2011 Mar; 26(1):183-7.
Score: 0.024
-
Comparison of chemotherapy education and patient preferences in community versus academic gynecology oncology clinics. J Oncol Pharm Pract. 2008 Mar; 14(1):31-6.
Score: 0.019
-
Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 2005 Jun; 97(3):840-4.
Score: 0.016